Ibandronate Sodium Patent Expiration

Ibandronate Sodium is Used for the treatment and prevention of osteoporosis in postmenopausal women. It was first introduced by Hoffmann La Roche Inc in its drug Boniva on May 16, 2003. 18 different companies have introduced drugs containing Ibandronate Sodium.


Ibandronate Sodium Patents

Given below is the list of patents protecting Ibandronate Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Boniva US5662918 Pharmaceutical agents containing diphosphonic acids and salts thereof Sep 02, 2014

(Expired)

Roche
Boniva US6143326 Oral pharmaceutical preparation containing ibandronat Apr 21, 2017

(Expired)

Hoffmann La Roche
Boniva US6294196 Pharmaceutical composition containing diphosphonic acid or salt thereof Oct 07, 2019

(Expired)

Hoffmann La Roche
Boniva US7192938 Method of treatment using bisphosphonic acid May 06, 2023

(Expired)

Hoffmann La Roche
Boniva US7410957 Method of treatment using bisphosphonic acid May 06, 2023

(Expired)

Hoffmann La Roche
Boniva US7718634 Method of treatment using bisphosphonic acid May 06, 2023

(Expired)

Hoffmann La Roche


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Ibandronate Sodium Generics

Several generic applications have been filed for Ibandronate Sodium. The first generic version for Ibandronate Sodium was by Mylan Pharmaceuticals Inc and was approved on Mar 19, 2012. And the latest generic version is by Nang Kuang Pharmaceutical Co Ltd and was approved on Jun 16, 2021.

Given below is the list of companies who have filed for Ibandronate Sodium generic.


1. ACCORD HLTHCARE

Accord Healthcare Inc has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 3MG BASE/3ML injectable Prescription INTRAVENOUS AP Feb 5, 2016


2. MYLAN PHARMS INC

Mylan Pharmaceuticals Inc has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Mylan Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 150MG BASE tablet Discontinued ORAL N/A Mar 19, 2012


3. MYLAN LABS LTD

Mylan Laboratories Ltd has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Mylan Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 3MG BASE/3ML injectable Prescription INTRAVENOUS AP Sep 2, 2014


4. NANG KUANG PHARM CO

Nang Kuang Pharmaceutical Co Ltd has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Nang Kuang Pharm Co.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 3MG BASE/3ML injectable Discontinued INTRAVENOUS N/A Jun 16, 2021


5. DR REDDYS LABS LTD

Dr Reddys Laboratories Ltd has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 150MG BASE

(reference standard)

tablet Prescription ORAL AB Apr 30, 2012


6. APOTEX INC

Apotex Inc has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Apotex Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 150MG BASE tablet Prescription ORAL AB Mar 19, 2012


7. ORBION PHARMS

Orbion Pharmaceuticals Private Ltd has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Orbion Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 150MG BASE tablet Prescription ORAL AB Mar 19, 2012


8. AVET LIFESCIENCES

Avet Lifesciences Ltd has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Avet Lifesciences.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 3MG BASE/3ML injectable Discontinued INTRAVENOUS N/A Sep 2, 2014


9. SUN PHARM INDUSTRIES

Sun Pharmaceutical Industries Inc has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Sun Pharm Industries.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 150MG BASE tablet Discontinued ORAL N/A Aug 15, 2012


10. SUN PHARM

Sun Pharmaceutical Industries Ltd has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Sun Pharm.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 3MG BASE/3ML injectable Discontinued INTRAVENOUS N/A Feb 14, 2014


11. AUROBINDO PHARMA

Aurobindo Pharma Ltd has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 150MG BASE tablet Prescription ORAL AB Mar 11, 2016


12. EUGIA PHARMA

Eugia Pharma Specialities Ltd has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Eugia Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 3MG BASE/3ML injectable Prescription INTRAVENOUS AP Aug 19, 2015


13. APOTEX

Apotex Inc has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Apotex.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 3MG BASE/3ML

(reference standard)

injectable Prescription INTRAVENOUS AP Oct 16, 2015


14. MACLEODS PHARMS LTD

Macleods Pharmaceuticals Ltd has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 150MG BASE tablet Prescription ORAL AB Oct 31, 2017


15. SAGENT PHARMS INC

Sagent Pharmaceuticals Inc has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Sagent Pharms Inc.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 3MG BASE/3ML injectable Prescription INTRAVENOUS AP Sep 2, 2014


16. WATSON LABS TEVA

Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 1 generic for Ibandronate Sodium. Given below are the details of the strengths of this generic introduced by Watson Labs Teva.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 150MG BASE tablet Discontinued ORAL N/A Mar 20, 2012